IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial ...
The market expects Beta Bionics, Inc. (BBNX) to deliver a year-over-year increase in earnings on higher revenues when it ...
Beta Bionics (NASDAQ:BBNX) reported fourth-quarter and full-year 2025 results on its earnings call Tuesday, highlighting ...
Analysts estimate that Beta Bionics will report an earnings per share (EPS) of $-0.39. Beta Bionics bulls will hope to hear ...
The consensus estimate for Q4 2025 revenue is $0.03 billion, and the earnings are expected to come in at -$0.42 per share. The full year 2025's revenue is expected to be $0.10 billion, and the ...
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management ...
Beta Bionics, Inc. (BBNX) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $1.82 per share a year ago. These figures ...
Patch pump under development with commercialization expected by the end of 2027 One of Orange County’s fastest-growing public companies only went public two months ago. Beta Bionics Inc.’s concept of ...